CD274 and non-small cell lung carcinoma: In addition, cemiplimab is approved for first‐line treatment in patients with advanced NSCLC with PD‐L1 expression levels of at least 50%, but regardless of the expression level of PD‐L1, cemiplimab combined with platinum‐based chemotherapy is needed to treat non‐squamous epithelial tissue to show efficacy in NSCLC [3].